Xiang Jingjing, Hong Zirui, Zhang Yu, Chen Junfa, Shen Jianping, Zhu Ni
Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Hangzhou, 310006, People's Republic of China.
Department of Emergency, The First Affiliated Hospital Of Ningbo University, Ningbo, People's Republic of China.
Immunotherapy. 2024 Apr;16(7):447-452. doi: 10.2217/imt-2023-0321. Epub 2024 Mar 5.
Daratumumab, a CD38 monoclonal antibody, has been widely used in patients with multiple myeloma. Although a variety of adverse events have been reported, consciousness impairment has not been reported yet. We report a case of encephalopathy associated with daratumumab. A 57-year-old male, diagnosed with relapsed multiple myeloma, was treated with daratumumab. He developed a loss of consciousness after the first administration. Cerebral spinal fluid and magnetic resonance imaging of the brain suggested encephalopathy. It is recommended to be aware of rare but life threatening side effects of daratumumab. We present a case of rare encephalopathy characterized by consciousness disorder associated with daratumumab, which was successfully resolved on prompt institution of steroids, although the mechanism was unknown.
达雷妥尤单抗是一种CD38单克隆抗体，已广泛应用于多发性骨髓瘤患者。尽管已报告了多种不良事件，但尚未有关于意识障碍的报告。我们报告一例与达雷妥尤单抗相关的脑病病例。一名57岁男性，诊断为复发性多发性骨髓瘤，接受达雷妥尤单抗治疗。首次给药后他出现意识丧失。脑脊液检查和脑部磁共振成像提示为脑病。建议关注达雷妥尤单抗罕见但危及生命的副作用。我们报告了一例罕见的以意识障碍为特征的与达雷妥尤单抗相关的脑病病例，尽管机制不明，但通过及时使用类固醇药物成功解决。
